Genomictree Inc. (KOSDAQ:228760)

Market Cap	255.27B -48.8%
Revenue (ttm)	2.95B -17.1%
Net Income	-9.03B
EPS	-373.14
Shares Out	24.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	344,625
Open	11,270
Previous Close	11,320
Day's Range	10,290 - 11,280
52-Week Range	9,930 - 33,300
Beta	0.09
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Genomictree

Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraDTect SARS-CoV-2 RT-qPCR...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 79
• Stock Exchange: KOSDAQ
• Ticker Symbol: 228760

Financial Performance

In 2025, Genomictree's revenue was 3.76 billion, an increase of 59.17% compared to the previous year's 2.36 billion. Losses were -8.99 billion, -12.27% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 12, 2026

Data Sources Report a data error